No Data
No Data
Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Vir Gets FDA Breakthrough Therapy Status for Two Drugs
Express News | Vir Biotechnology Inc - Phase 3 Eclipse Program to Begin in First Half of 2025
Express News | Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA Prime Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta
Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta
Loss-making Vir Biotechnology (NASDAQ:VIR) Has Seen Earnings and Shareholder Returns Follow the Same Downward Trajectory Over Past -80%
Den the Dragon : Good my friend
李飞Allyssa : Thank you for your daily dedication.
101726747 : ty
Den the Dragon : hit
Phuong999 : Thank you
View more comments...